Similarly, KDM4A was overexpressed in ESCC patients who did not respond to anti-PD1 therapy, and application of KDM4 inhibitor (KDM4-IN-4) followed by anti-PD1 therapy led to pronounced suppression of tumor growth in vivo [84]. Here, KDM4A is linked to neoplasm.